NCT01962298

Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex

Sugammadex and the Diaphragm: Recovery of Diaphragmatic Function and Neuromuscular Blockade. A Double-blind Randomized Controlled Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: University Hospital, Antwerp · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The effect of neuromuscular blocking agents (NMBA, e.g. rocuronium) on respiratory muscle activity is well known. However, since the availability of sugammadex, to our knowledge, no study has been conducted to evaluate the effect of this novel product on these muscles. Our hypothesis is that by applying a different strategy in the use of neuromuscular blocking agents and their reversal agents we might see a different activity of the respiratory muscles.

Conditions

• Diaphragmatic Dysfunction
• Muscle Weakness
• Muscle Fatigue

Interventions

Type	Name	Description
DRUG	sugammadex 2mg/kg
DRUG	neostigmine
DRUG	sugammadex 4mg/kg
DRUG	placebo
DRUG	Single rocuronium dose
DRUG	Repeated rocuronium dose
DRUG	Continuous rocuronium infusion

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2013-10-14
• Last updated: 2018-10-24
• Results posted: 2018-10-24

Locations

1 site across 1 country: Belgium